800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH
Back To Doctor Search

J. Nicholas Bodor, MD, PhD, MPH

J. Nicholas Bodor
Request Appointment

  • Assistant Professor, Department of Hematology/Oncology
  • Thoracic Oncology Program

Specialties

Thoracic Medical Oncology

Distinctions
2025 Top Doctors by Philadelphia magazine Emblem for Hospitals that are High-Performing for Leukemia, Lymphoma, and Myeloma 2024-2025
4.9
89 Patient Satisfaction Ratings
About Me
Ratings & Reviews
Publications
About Me
Education
  • Hematology and Oncology Fellowship, Fox Chase Cancer Center - Temple University Hospital Philadelphia, PA, 2017-20
  • Internal Medicine Residency, University of Maryland Medical Center, Department of Medicine Baltimore, MD, 2014-17
  • MD, Louisiana State University, School of Medicine New Orleans, LA, 2014
  • Postdoctoral Fellowship, Tulane University, School of Public Health and Tropical Medicine New Orleans, LA, 2009-10
  • PhD, Public Health Nutrition, Tulane University, School of Public Health and Tropical Medicine New Orleans, LA, 2009
  • MPH, Maternal and Child Health/Epidemiology, Tulane University, School of Public Health and Tropical Medicine New Orleans, LA, 2003
Board Certifications
  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology
Memberships
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • International Association for the Study of Lung Cancer
Awards and Honors
  • Philadelphia Magazine Top Doctors, 2024-25
  • ASCO Annual Meeting Merit Award American Society of Clinical Oncology Chicago, IL, 2018
No video provider was found to handle the given URL. See the documentation for more information.
  • Philadelphia Magazine Top Doctors, 2024
  • ASCO Annual Meeting Merit Award American Society of Clinical Oncology Chicago, IL, 2018
Ratings & Reviews

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Overall Care
4.9
Explained Things Clearly
5.0
Showed Courtesy & Respect
5.0
Discussed Treatment Options
4.9
Recommend Provider
4.9

Patient Comments

4.9 out of 5 (89 ratings, 6 comments)
02/10/2025

Dr Bodor is an excellent doctor.

02/04/2025

Was very comfortable with Dr BODOR and hope to continue my medical treatments with him. He is very knowledgeable and an awesome physician

12/30/2024

I am very lucky to be under Doctor Bodor's care. His team makes me feel like I have a chance to live. If any of the ratings not at the max highest rated, it's because I am a dying person and I am bitter.

09/30/2024

Dr. Bodor saved my life twice forever grateful

06/13/2024

If I could give Dr. Bodor a 100 I would. He is a wonderful doctor and I am so fortunate he is my physician!

Offices

Office Locations

Fox Chase Cancer Center

333 Cottman Avenue

Philadelphia, PA 19111

Phone: 888-369-2427

Publications
Publications
  1. O'Brien J, Bodor JN. Perioperative Immunotherapy in Non-Small Cell Lung Cancer. Curr Treat Options in Oncol. 2023 Dec 13. Online ahead of print.
  2. Bodor JN, Patel JC, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Phase II Randomized trial of carboplatin, pemetrexed, and bevacizumab with and without atezolizumab in stage IV non-squamous non-small cell lung cancer patients who harbor a sensitizing EGFR mutation or have never smoked. Clin Lung Cancer. 2023 24(7); e242-e246
  3. Bodor JN, Bauman JR, HandorfEA, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-LI and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Cancer Res Clin Oncol. 2023 149(5):1755-1763.
  4. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 12(25):2449-2458.
  5. Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF. Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLHl, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden {TMB) in 1,057 microsatellite instability-high solid tumors. Int J Cancer. 2020 May 24. doi: 10.1002/ijc.33l l 5.
  6. Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020 126:260-270.
  7. Bodor JN, Feliciano JL, Edelman MJ. Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation. Lung Cancer 2019 135:16-20
  8. Bodor JN, Kasireddy V, Borghaei H. First-line therapies for metastatic lung adenocarcinoma without a driver mutation. J Oncol Pract. 2018 Sep;14:529-535.
  9. Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. J Thorac Dis. 2018; 10 (Suppl 3):S480-S489.
  10. Bodor JN, Hutchison PL, Rose D. Car ownership and the association between fruit and vegetable availability and diet. Preventive Medicine 2013;57:903-905.
  11. Bodor JN, Rice JC, Farley TA, Swaim CM, Rose D. The association between obesity and urban food environments. Journal of Urban Health 2010;87:771-81.
  12. Bodor JN, Rice JC, Farley TA, Swaim CM, Rose D. Disparities in food access: Does aggregate availability of key foods from other stores offset the relative lack of supermarkets in African-American neighborhoods? Preventive Medicine 2010;51:63-7.